{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:50:40Z","timestamp":1791597040530,"version":"4.3.4"},"reference-count":137,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008866","name":"Changhai Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.isci.2026.117279","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:14:01Z","timestamp":1788279241000},"page":"117279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic reprogramming-mediated therapeutic resistance in renal cell carcinoma: Mechanisms and targeted intervention strategies"],"prefix":"10.1016","volume":"29","author":[{"given":"Han","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117279_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117279_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1450441","article-title":"Cancer metabolic reprogramming and precision medicine-current perspective","volume":"15","author":"Gao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2026.117279_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214360","article-title":"Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets","volume":"23","author":"di Meo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","article-title":"The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma","volume":"11","author":"Zhang","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.isci.2026.117279_bib5","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.3390\/ijms24098391","article-title":"PI3K\/AKT\/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL\/HIF Axis","volume":"24","author":"Badoiu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib6","first-page":"454","article-title":"Resistance to cancer immunotherapy in metastatic renal cell carcinoma","volume":"3","author":"Moreira","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.isci.2026.117279_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.31083\/j.fbl2911400","article-title":"DLX5 Promotes Radioresistance in Renal Cell Carcinoma by Upregulating c-Myc Expression","volume":"29","author":"Hu","year":"2024","journal-title":"Front. Biosci."},{"key":"10.1016\/j.isci.2026.117279_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbcan.2016.12.004","article-title":"Linking metabolic reprogramming to therapy resistance in cancer","volume":"1868","author":"Morandi","year":"2017","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.isci.2026.117279_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.trecan.2020.10.004","article-title":"Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance","volume":"7","author":"Bacci","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2026.117279_bib11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/biology9120474","article-title":"Lipid Metabolism and Resistance to Anticancer Treatment","volume":"9","author":"Germain","year":"2020","journal-title":"Biology"},{"key":"10.1016\/j.isci.2026.117279_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.trecan.2021.02.004","article-title":"Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids","volume":"7","author":"Pranzini","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2026.117279_bib13","article-title":"Targeting Alpha-Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD-1 Blockade Immunotherapy in Renal Cell Carcinoma","volume":"10","author":"Li","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218209","article-title":"Lactic acid promotes an MDSC-like phenotype via HIF1\u03b1 stabilization with impact on prognosis in renal cell carcinoma","volume":"639","author":"Babl","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2026.117279_bib15","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-25-3236","article-title":"Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney Cancer","author":"Wang","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib16","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","article-title":"Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism","volume":"25","author":"Peralta","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117279_bib17","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/s42255-025-01347-1","article-title":"Targeting MondoA-TXNIP restores antitumour immunity in lactic-acid-induced immunosuppressive microenvironment","volume":"7","author":"Xu","year":"2025","journal-title":"Nat. Metab."},{"key":"10.1016\/j.isci.2026.117279_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41581-025-00983-w","article-title":"Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors","volume":"21","author":"Burgers","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2026.117279_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41419-022-04576-4","article-title":"PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4\/ERK signaling pathway and accelerating glycolysis","volume":"13","author":"He","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.117279_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269432","article-title":"Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma","volume":"17","author":"Gu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117279_bib21","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11307-022-01747-9","article-title":"PET\/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine","volume":"24","author":"Pollard","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.isci.2026.117279_bib22","doi-asserted-by":"crossref","first-page":"13371","DOI":"10.18632\/oncotarget.3823","article-title":"Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma","volume":"6","author":"Lucarelli","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117279_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.amjms.2020.06.014","article-title":"6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming","volume":"360","author":"Cao","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-031-07634-3_1","article-title":"Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment","volume":"100","author":"Adhikari","year":"2022","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.isci.2026.117279_bib25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40170-016-0154-8","article-title":"Novel drugs that target the metabolic reprogramming in renal cell cancer","volume":"4","author":"van der Mijn","year":"2016","journal-title":"Cancer Metab."},{"key":"10.1016\/j.isci.2026.117279_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1664292","article-title":"Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications","volume":"13","author":"Yang","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.isci.2026.117279_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.58902","article-title":"G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression","volume":"19","author":"Zhang","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib29","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/ijms27062844","article-title":"Targeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma","volume":"27","author":"Ferreira","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib30","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.18632\/aging.101685","article-title":"Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma","volume":"10","author":"Lucarelli","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.isci.2026.117279_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.tem.2025.03.008","article-title":"Fumarate integrates metabolism and immunity in diseases","volume":"36","author":"Cheng","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.isci.2026.117279_bib32","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.molcel.2022.01.029","article-title":"Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma","volume":"82","author":"Ge","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2026.117279_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-023-05770-w","article-title":"Fumarate induces vesicular release of mtDNA to drive innate immunity","volume":"615","author":"Zecchini","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117279_bib34","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1038\/s41598-017-03980-7","article-title":"HIF-1-mediated suppression of mitochondria electron transport chain function confers resistance to lidocaine-induced cell death","volume":"7","author":"Okamoto","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117279_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.celrep.2015.06.006","article-title":"Suppression of PGC-1\u03b1 Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma","volume":"12","author":"LaGory","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117279_bib36","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/1878-0261.12499","article-title":"c-MYB- and PGC1a-dependent metabolic switch induced by MYBBP1A loss in renal cancer","volume":"13","author":"Felipe-Abrio","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2022.04.032","article-title":"Obesity in relation to renal cell carcinoma incidence and survival in three prospective studies","volume":"82","author":"Graff","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.117279_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002724","article-title":"The influence of obesity-related factors in the etiology of renal cell carcinoma\u2014A mendelian randomization study","volume":"16","author":"Johansson","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2026.117279_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-021-09996-w","article-title":"Lipid metabolism reprogramming in renal cell carcinoma","volume":"41","author":"Heravi","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.isci.2026.117279_bib40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/metabo11090608","article-title":"Renal lipid metabolism abnormalities in obesity and clear cell renal cell carcinoma","volume":"11","author":"Bobulescu","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.isci.2026.117279_bib41","series-title":"StatPearls [Internet]","article-title":"Biochemistry, fatty acid oxidation","author":"Talley","year":"2023"},{"key":"10.1016\/j.isci.2026.117279_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-00793-4_1","article-title":"Fatty acid synthase: structure, function, and regulation","volume":"99","author":"G\u00fcnenc","year":"2022","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.isci.2026.117279_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","article-title":"Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets","volume":"20","author":"Tan","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.isci.2026.117279_bib44","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1158\/2159-8290.CD-21-0211","article-title":"Cholesterol auxotrophy as a targetable vulnerability in clear cell renal cell carcinoma","volume":"11","author":"Riscal","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117279_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.727778","article-title":"The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC","volume":"11","author":"Qi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310479121","article-title":"Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma","volume":"121","author":"Sainero-Alcolado","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117279_bib47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00018-023-04965-8","article-title":"BCAT2 promotes melanoma progression by activating lipogenesis via the epigenetic regulation of FASN and ACLY expressions","volume":"80","author":"Tian","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.isci.2026.117279_bib48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/cells8030214","article-title":"Hypoxia-inducible factors and the regulation of lipid metabolism","volume":"8","author":"Mylonis","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.117279_bib49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.tibs.2025.06.005","article-title":"The HIF axes in cancer: Angiogenesis, metabolism, and immune-modulation","volume":"50","author":"Acu\u00f1a-Pilarte","year":"2025","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-73969-6","article-title":"Activation of the mTOR pathway enhances PPAR\u03b3\/SREBP-mediated lipid synthesis in human meibomian gland epithelial cells","volume":"14","author":"Jun","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117279_bib51","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.7150\/thno.70194","article-title":"SCD1\/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells","volume":"12","author":"Xuan","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.isci.2026.117279_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2445774","article-title":"Exploring the significance of fatty acid metabolism reprogramming in the pathogenesis of cancer and anticancer therapy","volume":"57","author":"Sun","year":"2025","journal-title":"Ann. Med."},{"key":"10.1016\/j.isci.2026.117279_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.32948\/auo.2023.12.30","article-title":"Lipid Metabolism Pathway and Renal Tumor Therapy","volume":"6","author":"Wang","year":"2023","journal-title":"Ann. Urol. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib54","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1038\/s41467-022-35036-4","article-title":"Dynamic partitioning of branched-chain amino acids-derived nitrogen supports renal cancer progression","volume":"13","author":"Sciacovelli","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117279_bib55","article-title":"The role of metabolic reprogramming in kidney cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib56","article-title":"Identification of an amino acid metabolism-associated gene signature predicting the prognosis and immune therapy response of clear cell renal cell carcinoma","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib57","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.21037\/tcr-23-344","article-title":"A polyamine metabolism risk signature for predicting the prognosis and immune therapeutic response of kidney cancer","volume":"12","author":"Li","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib58","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.copbio.2021.03.001","article-title":"Glutathione and its precursors in cancer","volume":"68","author":"Asantewaa","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.isci.2026.117279_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41419-024-06510-2","article-title":"Fumarate induces LncRNA-MIR4435-2HG to regulate glutamine metabolism remodeling and promote the development of FH-deficient renal cell carcinoma","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.117279_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70029","article-title":"The Glutamate\/GABA-Glutamine Cycle: Insights, Updates, and Advances","volume":"169","author":"Andersen","year":"2025","journal-title":"J. Neurochem."},{"key":"10.1016\/j.isci.2026.117279_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188559","article-title":"Metabolic reprogramming in renal cancer: events of a metabolic disease","volume":"1876","author":"Chakraborty","year":"2021","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.isci.2026.117279_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114552","article-title":"ASCT2 is a major contributor to serine uptake in cancer cells","volume":"43","author":"Conger","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117279_bib63","article-title":"Inhibition of GLS1 and ASCT2 synergistically enhances the anticancer effects in pancreatic Cancer cells","volume":"35","author":"Kim","year":"2025","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.isci.2026.117279_bib64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41581-023-00800-2","article-title":"Metabolic alterations in hereditary and sporadic renal cell carcinoma","volume":"20","author":"Coffey","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2026.117279_bib65","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/jcp.29969","article-title":"The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy","volume":"236","author":"Lai","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.isci.2026.117279_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41416-020-0874-y","article-title":"Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion","volume":"123","author":"Hornigold","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117279_bib67","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.3390\/cancers13143541","article-title":"Arginine signaling and cancer metabolism","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.117279_bib68","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s12276-024-01268-1","article-title":"PHGDH: a novel therapeutic target in cancer","volume":"56","author":"Lee","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.isci.2026.117279_bib69","first-page":"2715","article-title":"Integrated single-cell and bulk characterization of branched chain amino acid metabolism-related key gene BCAT1 and association with prognosis and immunogenicity of clear cell renal cell carcinoma","volume":"16","author":"Zheng","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.isci.2026.117279_bib70","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamaoncol.2021.4337","article-title":"Treatment selection in first-line metastatic renal cell carcinoma\u2014the contemporary treatment paradigm in the age of combination therapy: a review","volume":"8","author":"Navani","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines\u00ae insights: kidney cancer, version 2.2024: featured updates to the NCCN Guidelines","volume":"22","author":"Motzer","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.isci.2026.117279_bib72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.isci.2026.117279_bib73","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.euo.2025.01.001","article-title":"Results of stereotactic body radiation therapy for primary renal cell carcinoma in a large multicenter series","volume":"8","author":"Abancourt","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib74","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.3390\/ijms25126328","article-title":"Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells","volume":"25","author":"Amaro","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib75","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41419-024-06913-1","article-title":"DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT\/mTOR\/HIF1\u03b1 pathway","volume":"15","author":"Di","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.117279_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116209","article-title":"Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo","volume":"267","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2026.117279_bib77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s40001-024-01808-5","article-title":"Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification","volume":"29","author":"Lu","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.isci.2026.117279_bib78","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.3390\/ijms24043272","article-title":"Lipids as targets for renal cell carcinoma therapy","volume":"24","author":"Stepanovska Tanturovska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib79","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jare.2024.04.032","article-title":"MIER2\/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma","volume":"70","author":"Wei","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.isci.2026.117279_bib80","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1158\/0008-5472.CAN-23-0969","article-title":"Fatty acid oxidation mediated by malonyl-CoA decarboxylase represses renal cell carcinoma progression","volume":"83","author":"Zhou","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib81","doi-asserted-by":"crossref","DOI":"10.34133\/research.0539","article-title":"STAT2\/SLC27A3\/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma","volume":"7","author":"Lu","year":"2024","journal-title":"Research"},{"key":"10.1016\/j.isci.2026.117279_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/metabo11010001","article-title":"Metabolomic analysis to elucidate mechanisms of sunitinib resistance in renal cell carcinoma","volume":"11","author":"Sato","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.isci.2026.117279_bib83","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-030-93337-1_11","article-title":"Taurine and its anticancer functions: in vivo and in vitro study","volume":"1370","author":"Ma","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.isci.2026.117279_bib84","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1158\/0008-5472.CAN-24-1393","article-title":"De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma","volume":"85","author":"Teisseire","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib85","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/0008-5472.CAN-24-0050","article-title":"MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma","volume":"85","author":"Liu","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563303","article-title":"Impact of lactate on immune cell function in the tumor microenvironment: Mechanisms and therapeutic perspectives","volume":"16","author":"Gu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117279_bib87","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148549","article-title":"Fighting in a wasteland: deleterious metabolites and antitumor immunity","volume":"132","author":"Watson","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117279_bib88","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","article-title":"Unraveling the complex interplay between T cell metabolism and function","volume":"36","author":"Klein","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.117279_bib89","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/s41416-023-02412-w","article-title":"Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism","volume":"129","author":"Valcarcel-Jimenez","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117279_bib90","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/pharmaceutics13050762","article-title":"Targeting mitochondrial oncometabolites: a new approach to overcome drug resistance in cancer","volume":"13","author":"Godel","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.isci.2026.117279_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.680609","article-title":"Carney triad, Carney-Stratakis syndrome, 3PAS and other tumors due to SDH deficiency","volume":"12","author":"Pitsava","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2026.117279_bib92","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/s41418-024-01402-6","article-title":"Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer","volume":"31","author":"Lanzetti","year":"2024","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.isci.2026.117279_bib93","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1541-7786.MCR-19-0517","article-title":"Glutamine deprivation induces PD-L1 expression via activation of EGFR\/ERK\/c-Jun signaling in renal cancer","volume":"18","author":"Ma","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib94","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2023.04.006","article-title":"Modulation of T cells by tryptophan metabolites in the kynurenine pathway","volume":"44","author":"Stone","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib95","doi-asserted-by":"crossref","first-page":"66540","DOI":"10.18632\/oncotarget.11658","article-title":"Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer","volume":"7","author":"Trott","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117279_bib96","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/cas.14797","article-title":"Tryptophan 2, 3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma","volume":"112","author":"Sumitomo","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.isci.2026.117279_bib97","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","article-title":"Arginase I\u2013producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes","volume":"69","author":"Rodriguez","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib98","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.isci.2026.117279_bib99","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD 39 and CD 73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.117279_bib100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12967-023-04161-z","article-title":"Fatty acids metabolism affects the therapeutic effect of anti-PD-1\/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma","volume":"21","author":"Lin","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.117279_bib101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.117279_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202403107","article-title":"A novel nanozyme to enhance radiotherapy effects by lactic acid scavenging, ROS generation, and hypoxia mitigation","volume":"11","author":"Yao","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib103","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200067","article-title":"Emerging strategies to target cancer metabolism and improve radiation therapy outcomes","volume":"93","author":"Kery","year":"2020","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.isci.2026.117279_bib104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117279_bib105","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2\u03b1 Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib106","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117279_bib107","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.juro.2008.03.186","article-title":"Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells","volume":"180","author":"Horiguchi","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.isci.2026.117279_bib108","doi-asserted-by":"crossref","first-page":"C890","DOI":"10.1152\/ajpcell.00322.2014","article-title":"PPAR\u03b1 inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth","volume":"308","author":"Abu Aboud","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.isci.2026.117279_bib109","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-21-2972","article-title":"Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib110","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1172\/JCI87800","article-title":"Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers","volume":"127","author":"Okazaki","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117279_bib111","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbrc.2022.04.068","article-title":"Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma","volume":"611","author":"Kawakami","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.isci.2026.117279_bib112","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I\/II Trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib113","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib114","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1158\/1535-7163.MCT-16-0197","article-title":"Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth","volume":"15","author":"Abu Aboud","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2026.117279_bib115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/17512433.2024.2436433","article-title":"Targeting HIF-2\u03b1: the role of belzutifan in clear cell renal carcinoma management","volume":"18","author":"Vald\u00e9s","year":"2025","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.117279_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.isci.2026.117279_bib117","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12943-025-02457-w","article-title":"Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting","volume":"24","author":"Deng","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.117279_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.119989","article-title":"Salinomycin inhibits SREBP1 to sensitize ferroptosis and ameliorate sorafenib resistance in clear cell renal cell carcinoma","volume":"1872","author":"Su","year":"2025","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"key":"10.1016\/j.isci.2026.117279_bib119","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41419-023-05719-x","article-title":"PDIA4 confers resistance to ferroptosis via induction of ATF4\/SLC7A11 in renal cell carcinoma","volume":"14","author":"Kang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.117279_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259241","article-title":"The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma","volume":"16","author":"Emberley","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117279_bib121","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00432-014-1623-5","article-title":"Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models","volume":"140","author":"Ku","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib122","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41585-018-0118-6","article-title":"IL-23 links glutamine addiction and immune function","volume":"15","author":"Bradley","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.isci.2026.117279_bib123","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.eururo.2018.09.030","article-title":"Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion","volume":"75","author":"Fu","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.117279_bib124","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117279_bib125","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.3390\/cancers14163967","article-title":"OATD-02 validates the benefits of pharmacological inhibition of arginase 1 and 2 in cancer","volume":"14","author":"Grzybowski","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.117279_bib126","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-17-1589","article-title":"PHGDH as a key enzyme for serine biosynthesis in HIF2\u03b1-targeting therapy for renal cell carcinoma","volume":"77","author":"Yoshino","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib127","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.117279_bib128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2518245","article-title":"Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma","volume":"395","author":"Choueiri","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117279_bib129","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","article-title":"Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117279_bib130","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3566","article-title":"PHF8-GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma","volume":"9","author":"Peng","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.isci.2026.117279_bib131","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.apsb.2023.12.003","article-title":"Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer","volume":"14","author":"Liao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.isci.2026.117279_bib132","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41588-024-01662-5","article-title":"Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression","volume":"56","author":"Hu","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.isci.2026.117279_bib133","article-title":"Serum and urine metabolic fingerprints characterize renal cell carcinoma for classification, early diagnosis, and prognosis","volume":"11","author":"Xu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.isci.2026.117279_bib134","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.117279_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.153440","article-title":"Silencing MUC1 to regulate intracellular lipid metabolism: Overcoming sunitinib resistance and inhibiting metastasis in renal cell carcinoma","volume":"495","author":"Zeng","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.isci.2026.117279_bib136","doi-asserted-by":"crossref","first-page":"27487","DOI":"10.1021\/acsnano.4c08055","article-title":"Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and \u03b3-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma","volume":"18","author":"Lv","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.isci.2026.117279_bib137","article-title":"Photothermal therapy enhance the anti-mitochondrial metabolism effect of lonidamine to renal cell carcinoma in homologous-targeted nanosystem","volume":"34","author":"Chen","year":"2021","journal-title":"Nanomedicine."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422602657X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422602657X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:20:29Z","timestamp":1791595229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258900422602657X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":137,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S258900422602657X"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117279","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic reprogramming-mediated therapeutic resistance in renal cell carcinoma: Mechanisms and targeted intervention strategies","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117279"}}